VALENCIA, Calif. and MELBOURNE, Australia, Aug. 17, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a ...

Credit: Avita Medical. The RECELL System is a single-use, autologous cell harvesting device. The Food and Drug Administration (FDA) has approved the RECELL ® System for the treatment of vitiligo. The ...

AVITA Medical, a regenerative medicine company, is pioneering the RECELL System - a patient-specific skin cell solution aimed at revolutionizing skin restoration. The company saw a 40% increase in ...

VALENCIA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (RCEL) (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The expanded approval of Recell includes full-thickness ...

Please provide your email address to receive an email when new articles are posted on . Melanocyte-keratinocyte transplant procedures are rare in the U.S. due to a need for specialized equipment. The ...

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization ...

You may send us your comments on this form by clicking the button below. You will first be asked to supply your name, email address, and location. You must then acknowledge our data protection ...

Global evidence and real-world data demonstrate the clinical, operational, and economic impact of AVITA Medical’s RECELL System across wound types and patient populations VALENCIA, Calif., Nov. 03, ...

The External Assessment Centre excluded all the studies identified by the sponsor because they were outside the scope of the evaluation, although it did recognise that the studies contained useful ...